MedTrace Logo

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

NCT05465707 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-20

No results posted yet for this study

Summary

A study of CM313 in subjects with systemic lupus erythematosus

Conditions

Interventions

BIOLOGICAL

CM313 2 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 4 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 8 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

CM313 16 mg/kg

Once 1 week, intravenous infusion.

BIOLOGICAL

Placebo

Once 1 week, intravenous infusion.

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-30
Primary Completion
2023-10-30
Completion
2023-10-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465707 on ClinicalTrials.gov